WallStSmart

HCW Biologics Inc (HCWB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCW Biologics Inc generates 788% more annual revenue ($6.59M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -34.7%. HCWB earns a higher WallStSmart Score of 51/100 (C-).

HCWB

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 4.0Value: 5.0Quality: 3.0
Piotroski: 3/9Altman Z: -7.94

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCWB3 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
129081.0%10/10

Revenue surging 129081.0% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

HCWB4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.99M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.143/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : HCWB

The strongest argument for HCWB centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 129081.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : HCWB

The primary concerns for HCWB are EPS Growth, Market Cap, Debt/Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

HCWB profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

HCWB carries more volatility with a beta of 2.30 — expect wider price swings.

HCWB is growing revenue faster at 129081.0% — sustainability is the question.

HCWB generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

HCWB scores higher overall (51/100 vs 24/100) and 129081.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCW Biologics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

HCW Biologics Inc is a forward-thinking biotechnology company focused on pioneering immunotherapies and vaccine technologies to tackle pressing health issues such as cancer and infectious diseases. Utilizing its proprietary platforms to amplify immune responses, HCW Biologics is actively expanding a promising pipeline of clinical candidates poised to make significant impacts in patient care. With a keen commitment to strategic partnerships and addressing urgent medical needs, the company aims to establish itself as a competitive force in the biotechnology landscape, presenting compelling investment opportunities that align with the evolving dynamics of the healthcare sector.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?